The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose

Chagla, Zain

doi:10.7326/acpj202102160-015

Cited by 106 publications

(104 citation statements)

References 0 publications

Supporting

Mentioning

101

Contrasting

Order By: Relevance

“…To date, three vaccines are administered worldwide. Among them, the Pfizer and Moderna mRNA vaccines are approximately 95% effective in preventing the development of COVID‐19 in adults 16 or 18 years of age and older 3–5 . AstraZeneca's chimpanzee adenovirus vector vaccine has a protective effect (VE) of approximately 60%–90% against the development of COVID‐19 in adults 18 years of age and older 6,7 .…”

Section: Introductionmentioning

confidence: 99%

Anti‐SARS‐CoV‐2 vaccination strategy for pregnant women in Japan

Hayakawa

Komine‐Aizawa

Takada

et al. 2021

J of Obstet and Gynaecol

View full text Add to dashboard Cite

The current COVID‐19 pandemic is a global concern. The recent introduction of vaccines has provided a reason for hope, but new problems, such as vaccine hesitancy, have arisen. One of the most important of these issues is the safety of vaccines for pregnant women. In this article, we collected worldwide indications for vaccination, including women who are pregnant or who wish to become pregnant, and reports of adverse reactions to COVID‐19 vaccination. The Japan Society of Obstetrics and Gynecology and the Japanese Society of Infectious Diseases in Obstetrics and Gynecology have published recommendations for the vaccination of pregnant women with a COVID‐19 vaccine. The guidelines are as follows: (1) pregnant women should not be excluded from vaccination; (2) informed consent should be obtained before vaccination; (3) healthcare workers and pregnant women with complications such as diabetes, hypertension, and obesity should be vaccinated preferentially; (4) vaccination should be avoided until 12 weeks of gestation during organogenesis; (5) spouse and family members should be vaccinated actively; and (6) nursing mothers are not particularly affected. This policy has been adopted in government guidelines. Additional efforts should be made to protect pregnant women from infection and severe illness with COVID‐19 by eliminating vaccine hesitancy.

show abstract

Section: Introductionmentioning

confidence: 99%

Anti‐SARS‐CoV‐2 vaccination strategy for pregnant women in Japan

Hayakawa

Komine‐Aizawa

Takada

et al. 2021

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…Among the major vaccines that are currently administered among the population worldwide, the mRNA vaccines, i.e., Pfizer-BioNTech (BNT162b1) and Moderna (mRNA 1273) vaccines, are under phase III trial with the observable efficiency (94%) [ 2 , 10 , 11 ]. As reported earlier, the mRNA encoding the spike (S) protein is protected by a submersible lipid nanoparticle; and once administered into the host, the expression of the spike protein occurs as a result of the host immune response as shown in Figure 3 [ 2 ].…”

Section: Major Covid-19 Vaccinesmentioning

confidence: 99%

A Review on the Effectivity of the Current COVID-19 Drugs and Vaccines: Are They Really Working Against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants?

Noor

2021

Curr Clin Micro Rpt

View full text Add to dashboard Cite

Purpose of Review In order to eradicate the COVID-19 pandemic, scientists around the world have been working very hard for a year or more with the motto of designing effective drugs and vaccines against the severe acute respiratory coronavirus 2 (SARS-CoV-2). Along with the positive results with the antiviral drugs and a few commercialized vaccines, the unresponsiveness as well as some side effects of such therapies have also been noticed, possibly due to the emergence of the SARS-CoV-2 variants. Therefore, current review summarized the actual effectiveness of the antivirals and vaccines which are in current use for the treatment of the COVID-19 patients. Recent Findings So far, some drugs have been found with hopeful results among which remdesivir and arbidol are with momentous clinical progress. Besides drug designing, vaccine development has been a major effort whereby the mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) vaccines showed the required efficacy and have been approved by the US Food and Drug Administration (USFDA). Summary While a number of existing/repurposed/repositioned or new drugs and the currently used commercial vaccines against SARS-CoV-2 apparently seem to be effective against COVID-19 mitigation, the new variants of the virus as well as the recently increased cases raised the doubt about the usefulness of these agents. Current review figured out the efficacy of different drugs and vaccines in terms of their action potential against SARS-CoV-2 and further recommended some useful measures which may be useful for future remedies.

show abstract

“…This vaccine received FDA emergency approval in the US, while it has been fully approved in other countries (137). Further studies have shown that the BNT162b2 vaccine has 95% efficacy in preventing a COVID-19 infection 7 days after the second dose (137,138). Of note, the nanoparticles that deliver the mRNA contain polyethylene glycol (PEG), a compound that has been linked to unwanted severe allergy-like symptoms.…”

Section: Vaccinesmentioning

confidence: 99%

Nanomedicine: A Diagnostic and Therapeutic Approach to COVID-19

2021

View full text Add to dashboard Cite

The SARS-CoV-2 virus is causing devastating morbidity and mortality worldwide. Nanomedicine approaches have a high potential to enhance conventional diagnostics, drugs and vaccines. In fact, lipid nanoparticle/mRNA vaccines are already widely used to protect from COVID-19. In this review, we present an overview of the taxonomy, structure, variants of concern, epidemiology, pathophysiology and detection methods of SARS-CoV-2. The efforts of repurposing, tailoring, and adapting pre-existing medications to battle COVID-19 and the state of vaccine developments are presented. Next, we discuss the broad concepts and limitations of how nanomedicine could address the COVID-19 threat. Nanomaterials are particles in the nanometer scale (10–100 nm) which possess unique properties related to their size, polarity, structural and chemical composition. Nanoparticles can be composed of precious metals (copper, silver, gold), inorganic materials (graphene, silicon), proteins, carbohydrates, lipids, RNA/DNA, or conjugates, combinations and polymers of all of the aforementioned. The advanced biochemical features of these nanoscale particles allow them to directly interact with virions and irreversibly disrupt their structure, which can render a virus incapable of replicating within the host. Virus-neutralizing coats and surfaces impregnated with nanomaterials can enhance personal protective equipment, hand sanitizers and air filter systems. Nanoparticles can enhance drug-based therapies by optimizing uptake, stability, target cell-specific delivery, and magnetic properties. In fact, recent studies have highlighted the potential of nanoparticles in different aspects of the fight against SARS-CoV-2, such as enhancing biosensors and diagnostic tests, drug therapies, designing new delivery mechanisms, and optimizing vaccines. This article summarizes the ongoing research on diagnostic strategies, treatments, and vaccines for COVID-19, while emphasizing the potential of nanoparticle-based pharmaceuticals and vaccines.

show abstract

The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose

Cited by 106 publications

References 0 publications

Anti‐SARS‐CoV‐2 vaccination strategy for pregnant women in Japan

Anti‐SARS‐CoV‐2 vaccination strategy for pregnant women in Japan

A Review on the Effectivity of the Current COVID-19 Drugs and Vaccines: Are They Really Working Against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants?

Nanomedicine: A Diagnostic and Therapeutic Approach to COVID-19

Contact Info

Product

Resources

About